PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study

被引:0
作者
J Familiades
M Bousquet
M Lafage-Pochitaloff
M-C Béné
K Beldjord
J De Vos
N Dastugue
E Coyaud
S Struski
C Quelen
N Prade-Houdellier
S Dobbelstein
J-M Cayuela
J Soulier
N Grardel
C Preudhomme
H Cavé
O Blanchet
V Lhéritier
A Delannoy
Y Chalandon
N Ifrah
A Pigneux
P Brousset
E A Macintyre
F Huguet
H Dombret
C Broccardo
É Delabesse
机构
[1] INSERM U563,Department of Genetics
[2] Centre de Physiopathologie Toulouse Purpan,Department of Immunology
[3] Université Toulouse III Paul Sabatier,Department of Hematology
[4] CHU Timone,Department of Hematology
[5] CHU Nancy,Department of Hematology
[6] CHU Necker,Department of Hematology
[7] INSERM U847,Department of Genetics
[8] Biothérapie des cellules souches normales et cancéreuses,Department of Hematology
[9] Université Montpellier I,Department of Hematology
[10] CHU Toulouse,Division of Hematology
[11] CHU Saint-Louis,Department of Hematology
[12] CHU Lille,Department of Pathology
[13] CHU Robert-Debré,undefined
[14] CHU Angers,undefined
[15] GRAALL,undefined
[16] CHU Lyon,undefined
[17] Cliniques Universitaires Saint-Luc,undefined
[18] Hôpital Universitaire,undefined
[19] CHU Bordeaux,undefined
[20] CHU Toulouse,undefined
来源
Leukemia | 2009年 / 23卷
关键词
BCP-ALL; oncogenesis; BCR-ABL1; PAX5; TCF3-PBX1;
D O I
暂无
中图分类号
学科分类号
摘要
Adult and child B-cell progenitor acute lymphoblastic leukemia (BCP-ALL) differ in terms of incidence and prognosis. These disparities are mainly due to the molecular abnormalities associated with these two clinical entities. A genome-wide analysis using oligo SNP arrays recently demonstrated that PAX5 (paired-box domain 5) is the main target of somatic mutations in childhood BCP-ALL being altered in 38.9% of the cases. We report here the most extensive analysis of alterations of PAX5 coding sequence in 117 adult BCP-ALL patients in the unique clinical protocol GRAALL-2003/GRAAPH-2003. Our study demonstrates that PAX5 is mutated in 34% of adult BCP-ALL, mutations being partial or complete deletion, partial or complete amplification, point mutation or fusion gene. PAX5 alterations are heterogeneous consisting in complete loss in 17%, focal deletions in 10%, point mutations in 7% and translocations in 1% of the cases. PAX5 complete loss and PAX5 point mutations differ. PAX5 complete loss seems to be a secondary event and is significantly associated with BCR-ABL1 or TCF3-PBX1 fusion genes and a lower white blood cell count.
引用
收藏
页码:1989 / 1998
页数:9
相关论文
共 167 条
[1]  
Cobaleda C(2007)Pax5: the guardian of B cell identity and function Nat Immunol 8 463-470
[2]  
Schebesta A(2006)A PANorama of Nat Rev Cancer 6 52-62
[3]  
Delogu A(1992) genes in cancer and development Genes Dev 6 1589-1607
[4]  
Busslinger M(2007)Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis J Immunol 178 3031-3037
[5]  
Robson EJ(1999)Reporter gene insertions reveal a strictly B lymphoid-specific expression pattern of pax5 in support of its B cell identity function Nature 401 556-562
[6]  
He SJ(1999)Commitment to the B-lymphoid lineage depends on the transcription factor Pax5 Nature 401 603-606
[7]  
Eccles MR(2007)Long-term Nature 449 473-477
[8]  
Adams B(1996) reconstitution of T-cell development by Pax5-deficient B-cell progenitors Blood 88 4110-4117
[9]  
Dorfler P(1996)Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors Proc Natl Acad Sci USA 93 6129-6134
[10]  
Aguzzi A(2005)The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene Genes Chromosomes Cancer 44 218-223